Simplex Quantum welcomed Dr. Marco Perez, a Stanford cardiac electrophysiology expert and Apple Heart Study investigator, as an advisor to guide its AI-driven heart failure technology.
Simplex Quantum was selected for the MedTech Innovator Asia Pacific 2025 Accelerator, recognizing it among the region's top 20 medtech startups.
Simplex Quantum and the University of Tokyo announced a breakthrough AI technology for continuous heart failure monitoring.
Simplex Quantum was selected to pitch its AI-driven heart failure technology at the MedTech Innovator APAC 2025 event in Singapore.
Simplex Quantum presented its AI-driven heart failure risk identification technology at the LSI USA 2025 conference.
Simplex Quantum expanded into Asia with a new patent granted in India and a strategic healthcare initiative in Indonesia.
Research on Simplex Quantum's AI-powered heart failure risk identification was published in JACC: Basic to Translational Science.
Simplex Quantum presented its AI-powered heart failure risk identification technology at the THT 2024 Shark Tank innovation competition.
The University of Tokyo Hospital launched a large-scale clinical study examining AI-derived heart failure output and exercise capacity using Apple Watch.
Simplex Quantum closed a JPY550 million Series A funding round to advance its AI-driven heart failure technology.
Simplex Quantum secured a US patent for biometric authentication technology based on electrocardiogram signals.
Simplex Quantum completed US registration of a patent for AI technology that stages heart failure from ECG data, developed with University of Tokyo Hospital.